Related Experiment Video

Updated: Jul 26, 2025

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

9.8K

Nox4 as a novel therapeutic target for diabetic vascular complications

Dongxia Wang1, Jiaying Li2, Gang Luo3

  • 1Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Food Nutrition and Safety, Ministry of Education Key Laboratory of Environment, Wuhan, 430030, China; Department of Nutrition and Food Hygiene, School of Public Health, Hebei Medical University, Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, 050017, China.

Redox Biology
|June 15, 2023
PubMed

Insights

Oxidative stress from Nox4 contributes to diabetic microvascular complications like kidney disease. Targeting Nox4 with drugs or diet may prevent and treat these serious diabetes issues.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pathophysiology

Background:

  • Diabetic vascular complications affect microvascular and macrovascular systems.
  • Oxidative stress is implicated in diabetic microvascular complications, including nephropathy, retinopathy, neuropathy, and cardiomyopathy.
  • The Nox family of NADPH oxidases is a key source of reactive oxygen species (ROS) and regulates redox signaling in diabetes.

Purpose of the Study:

  • To review the role and regulation of Nox4 in diabetic microangiopathies.
  • To highlight novel advances in Nox4 upregulation in diabetic kidney disease.
  • To explore new mechanisms, including epigenetics, by which Nox4 regulates diabetic microangiopathy.

Main Methods:

  • Literature review of current knowledge on Nox4.
  • Analysis of recent findings on Nox4 upregulation in diabetic kidney disease.
  • Examination of epigenetic and other novel regulatory mechanisms of Nox4.

Main Results:

  • Nox4 upregulation exacerbates various cell types in diabetic kidney disease.
  • Nox4 plays a significant role in the pathogenesis of diabetic microangiopathy through various regulatory mechanisms.
  • Evidence links Nox4 to diabetic macroangiopathy.

Conclusions:

  • Nox4 is a critical mediator of diabetic microvascular complications.
  • Targeting Nox4 presents a promising therapeutic strategy for diabetic microangiopathy.
  • Further research into Nox4 regulation and therapeutic interventions is warranted.
Keywords:
Diabetic vascular complicationsDietary strategiesEpigenetic regulationNox4Nox4 inhibitors

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.0K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K